2017 Archive


Cohort Expansion In Select Tumors of Interest NEW YORK and ANN ARBOR, Mich., Oct. 19, 2017 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced the initiation of the Phase 2a portion of the company’s Phase 1/2a ARGON study of its novel immuno-oncology therapeutic candidate, LYC-55716 is a… Read More

Preliminary Findings from Phase 1/2a Trial Demonstrate LYC-55716 Was Well-Tolerated Durable Disease Stabilization Observed in Heavily Pretreated Patients NEW YORK and ANN ARBOR, Mich., September 11, 2017 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the first presentation of clinical findings from the initial three cohorts of… Read More

NEW YORK and ANN ARBOR, Mich., Mar. 13, 2017 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today that Pablo J. Cagnoni, M.D., has been elected to the Company’s Board of Directors, effective immediately. The Company also announced that Timothy M. Mayleben will step down from his position on… Read More

First-In-Class RORgamma Agonist to Begin Phase 1 – Dose Finding and Safety Assessment NEW YORK and ANN ARBOR, Mich., January 4, 2017 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the initiation of a Phase 1/2a clinical trial of the Company’s novel immuno-oncology therapeutic candidate LYC-55716, in patients… Read More